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Abstract In recent years the number of disorders known to
affect amino acid synthesis has grown rapidly. Nor is it just the
number of disorders that has increased: the associated clinical
phenotypes have also expanded spectacularly, primarily due
to the advances of next generation sequencing diagnostics. In
contrast to the Bclassical^ inborn errors of metabolism in cat-
abolic pathways, in which elevated levels of metabolites are
easily detected in body fluids, synthesis defects present with
low values of metabolites or, confusingly, even completely
normal levels of amino acids. This makes the biochemical
diagnosis of this relatively new group of metabolic diseases
challenging. Defects in the synthesis pathways of serine me-
tabolism, glutamine, proline and, recently, asparagine have all
been reported. Although these amino acid synthesis defects
are in unrelated metabolic pathways, they do share many clin-
ical features. In children the central nervous system is primar-
ily affected, giving rise to (congenital) microcephaly, early
onset seizures and varying degrees of mental disability. The
brain abnormalities are accompanied by skin disorders such as
cutis laxa in defects of proline synthesis, collodion-like skin
and ichthyosis in serine deficiency, and necrolytic erythema in
glutamine deficiency. Hypomyelination with accompanying
loss of brain volume and gyration defects can be observed
on brain MRI in all synthesis disorders. In adults with defects
in serine or proline synthesis, spastic paraplegia and several
forms of polyneuropathy with or without intellectual disability
appear to be the major symptoms in these late-presenting
forms of amino acid disorders. This review provides a com-
prehensive overview of the disorders in amino acid synthesis.
Introduction
In recent years exciting developments have taken place in the
discovery of disorders of amino acid synthesis. Several new
disorders have been reported as well as new phenotypes for
already known amino acid synthesis deficiencies, which is
mainly due to next generation sequencing of cohorts of pa-
tients with similar clinical phenotypes. A comprehensive
overview of these recent developments in amino acid synthe-
sis deficiencies will be presented here.
We all are aware of the fact that amino acids are the build-
ing blocks for peptide and protein synthesis and that they
perform important functions in intermediate metabolism.
However, many amino acids have specific cellular functions
of their own, in neurotransmission for instance, or energy
metabolism and detoxification. Historically, the biochemical
analysis of elevated levels of amino acids or their degradation
products in body fluids has been the cornerstone of diagnosing
inborn errors of metabolism. In 1996, Jaeken and colleagues
reported, for the first time, defects in the synthesis pathway of
the amino acid serine in children with severe neurological
symptoms. Low levels of serine and (glycine) in plasma and
cerebrospinal fluid (CSF) were the major diagnostic clues to
indicate a serine deficiency disorder. Since then, defects in
other amino acids synthesis pathways have been reported.
The study of patients with these synthesis defects unravels
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new and unique functions of the amino acids involved, for
instance in foetal development of the central nervous system
or maintenance of the peripheral nervous system. We have
also recently learned that these disorders can give rise to a
whole spectrum of clinical symptoms varying from lethal de-
velopmental defects to late onset adult spastic paraparesis. The
detection of amino acid synthesis deficiencies poses specific
challenges to our biochemical diagnostic procedures because
low values are easily missed, especially in milder phenotypes.
Much to our surprise, in some disorders, the plasma or CSF
concentrations of amino acids are non-informative, thus ne-
cessitating the use of sequencing techniques to confirm a clin-
ical diagnosis.
Awareness of amino acid synthesis disorders is important
because of the potential therapeutic consequences and the
sometimes very narrow window of opportunity to alter the
course of the disease and prevent neurological damage.
Serine deficiency
Defects in the genes encoding the three enzymes of the L-
serine synthetic pathway have been reported and, not surpris-
ingly, they all give rise to similar clinical phenotypes. L-serine
is synthesized from the glycolytic intermediate 3-
phosphoglycerate via three enzymatic conversions. The en-
zymes involved are 3-phosphoglycerate dehydrogenase (3-
PGDH, OMIM 606879), 3-phosphohydroxypyruvate amino-
transferase (PSAT, OMIM 610936) and phosphoserine phos-
phatase (PSP, OMIM 172480).
When serine deficiency disorders were first reported in
paediatric patients it appeared that there were some differ-
ences in phenotype between the three defects. However, with
recent insights obtained through whole-exome sequencing, it
is now obvious that it is not possible to discriminate the dif-
ferent gene defects on clinical grounds. Molecular defects in
the genes encoding the three enzymes can present with iden-
tical phenotypes ranging from a severe lethal antenatal pheno-
type to a milder adult onset polyneuropathy phenotype.
However, recognition of serine deficiency is important be-
cause good treatment results have been reported with L-
serine therapy.
Lethal serine deficiency phenotype (Neu-Laxova
syndrome)
The severe and lethal serine deficiency phenotype was already
known as Neu-Laxova syndrome (NLS). In 2014, two differ-
ent groups published mutations in serine synthesis genes in
patients with this Neu-Laxova syndrome (Acuna-Hidalgo et al
2014, Shaheen et al 2014). From this it was obvious that
defects in all three genes can give rise to the same clinical
phenotype.
NLS causes intrauterine or early postnatal death. Affected
children present with dysmorphic features consisting of prop-
tosis of the eyes, abnormal eyelids, microcephaly, small round
mouth, extensive skeletal abnormalities with contractures and
webbing of fingers and toes; skin abnormalities resembling a
collodion-like skin, and multiple structural abnormalities of
the central nervous system with neural tube defects, cortical
dysplasia, enlarged ventricular spaces and structural abnor-
malities of the cerebellum. Defects in serine metabolism were
detected through whole exome sequencing collaborations, and
not through detection of low values of serine in plasma.
Limited data are available on serine concentrations in body
fluids in patients with NLS, but in my personal experience,
plasma serine values can be very low (<30 μmol/L). No treat-
ment with L-serine has been reported in this severe phenotype,
but given the extensive and very early onset developmental
defects, successful treatment seems doubtful.
The 3-PGDH knock out mouse published some years ago
verymuch resembles the NLS phenotype and, so far, rescue of
the severe developmental defects in mice with L-serine thera-
py has not been reported (Yoshida et al 2004).
Infantile serine deficiency phenotype
Themajority of children with serine deficiency suffer from the
infantile phenotype, with phosphoglycerate dehydrogenase
deficiency as the major cause. The first cases reported by
Jaeken et al (1996) can also be classified within this pheno-
type. Many of the children were born after intrauterine growth
retardation and presented with congenital microcephaly. After
birth, intractable seizures developed within weeks to months,
and little to no psychomotor development was observed once
seizures are present. Children subsequently developed a se-
vere spastic quadriplegia during the first years of life.
It is important to recognize that congenital microcephaly
and seizures are not obligatory. Some children present first
with severe psychomotor disability accompanied by second-
ary microcephaly and failure to thrive (Brassier et al 2016).
One of the other symptoms regularly seen in infants is con-
genital cataracts (Tabatabaie et al 2010).
As in many other inborn errors of metabolism that gives
rise to an encephalopathy, no specific seizure or EEG pattern
is observed in serine deficiency and infantile spasms, tonic-
clonic seizures, tonic, atonic, gelastic and myoclonic seizures
have all been reported. The same is true for associated EEG
abnormalities; both hypsarithmia and multifocal seizure activ-
ity evolving towards Lennox-Gastaut syndrome have been
observed. Although the clinical seizures can respond rapidly
to therapy (within weeks), normalization or improvement of
EEG abnormalities may take much longer, in some cases as
long as 6–12 months (de Koning et al 1998; Brassier et al
2016). Cranial MRI in patients with serine deficiency shows
a profound decrease of cerebral white matter volume due to
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hypomyelination (de Koning et al 2000). Cerebellar abnor-
malities were observed on MRI in only one patient with
PSAT deficiency (reported by Hart et al 2007). However, giv-
en the extensive cerebellar defects that can be observed in
NLS, cerebellar abnormalities will likely be present in more
patients with serine deficiency than reported so far.
Juvenile serine deficiency phenotype
At present, only one family has been reported with a juvenile
onset, much milder serine deficiency phenotype (Tabatabaie
et al 2011). In two sibs, who acquired normal early develop-
mental milestones but subsequently developed moderate de-
velopmental disability, atypical absence seizures began at
school age. Microcephaly was not present in these patients,
nor were there pyramidal signs. The patients were diagnosed
as teenagers because of low values of serine in plasma and
later also found in CSF. This diagnostic evaluation was done
as part of a work-up for their developmental delay. At that
time, one of the two sibs also had severe behavioural abnor-
malities and mood disturbances. Cranial MRI in both adoles-
cents was normal without any signs of hypomyelination. The
serine deficiency was caused by mutations in PHGDH.
With only these two patients reported in the literature, it is
difficult to speculate on the expanded clinical phenotype that
may yet occur in these milder juvenile onset forms of serine
deficiency.
Adult serine deficiency phenotype
Méneret et al (2012) reported an adult patient with serine
deficiency also caused by 3-PGDH deficiency. This pa-
tient was diagnosed with mild mental disability and mild
cerebellar ataxia in childhood, but developed a progres-
sive polyneuropathy in adulthood. In addition, congenital
cataract was operated in infancy, clearly demonstrating
that overlapping symptoms between the different clinical
serine deficiency phenotypes can occur in individual pa-
tients. Given the role of L-serine in myelin synthesis and
the fact that defects in serine palmitoyltransferase are a
well-known cause of polyneuropathy (hereditary sensory
and autonomic neuropathy type 1, OMIM 605712 and
605,713), it is very likely that adult patients exist who
suffer only from polyneuropathy and represent the very
mild end of the spectrum of serine deficiency. I am aware
of more adults with mild serine deficiency with predom-
inant polyneuropathy, a phenotype l ikely to be
underdiagnosed (unpublished data).
Diagnosis
Remarkably, the biochemical abnormalities found in all pa-
tients reported with either the infantile, juvenile or adult
phenotype were identical in plasma and CSF, and so a diag-
nosis of serine deficiency can be suspected from routine ami-
no acid analysis in plasma and CSF at any age. The values in
plasma and CSF were quite similar in all phenotypes and do
not correlate with disease severity, meaning that the pheno-
type cannot be predicted from the results of amino acid anal-
ysis. Serine deficiency is more pronounced in CSF, and is not
influenced by the absorption of amino acids from the diet, an
important confounder of plasma amino acids analyses.
Analysis of urine amino acids to diagnose serine deficiency
is not helpful because, for still unclear reasons, amino acid
excretion is normal in patients. While enzymatic assays are
available for the three L-serine synthesis enzymes, enzyme
testing is being replaced more and more by DNA diagnostics.
This is due to problems in the availability of the substrate
required for the 3-PGDH assay and the debated sensitivity
of the other assays (Hart et al 2007).
Treatment
Successful treatment with L-serine has been reported in pa-
tients with the infantile, juvenile and adult phenotypes.
Patients with infantile 3-PGDH deficiency can be treated
with oral supplementation of a high dose of L-serine (500–
700 mg/kg/day) and, for selected children with an insufficient
response of their seizures to L-serine monotherapy, glycine
(200–300 mg/kg/day) can be added to the treatment (de
Koning et al 1998). Treatment with amino acids, in general,
has a good effect on wellbeing and behaviour as well as on the
patient’s seizure frequency. In some patients, the seizures will
disappear and accompanying EEG abnormalities will resolve.
In others, the seizure frequency significantly improves.
Unfortunately, amino acid therapy does not have a positive
effect on psychomotor development in symptomatic patients
even when their seizures are responding. No progress, or only
very limited progress, in psychomotor development has been
observed during (long term) treatment follow-up (de Koning
et al 2002; Brassier et al 2016; personal observations).
However, treatment can be successful when amino acid ther-
apy is initiated before symptoms arise, either as antenatal L-
serine therapy given to the mother or as immediate postnatal
therapy on the first day of life in still asymptomatic patients
(de Koning et al 2004; Hart et al 2007).
Interestingly, patients with the juvenile and adult pheno-
type require much lower dosages of L-serine than young chil-
dren do. In adolescents and adults good treatment results were
obtained with 100–150 mg/kg/day L-serine without added
glycine to the treatment. Dose finding studies have not been
performed in adults but, in the patient reported by Méneret
et al (2012), 80 mg/kg/day L-serine was insufficient to correct
the biochemical abnormalities in CSF but correction did occur
with 100-150 mg/kg/day.
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It is unclear what the most appropriate age would be to
switch from higher to lower doses of L-serine in children
growing older and becoming adolescents. L-Serine treatment
in the juvenile patients reported by Tabatabaie et al (2011) was
initiated at 15 years of age, so it seems safe to adjust the dose
of L-serine from around this age.
Serine deficiency mimic and secondary serine deficiency
Interestingly, mutations in the gene encoding the major serine
transporter SLC1A4 (OMIM 600229) leading to a defect in the
ASCT 1 transporter, give rise to symptoms similar to those
seen in serine synthesis disorders. Srour et al (2015) reported
two sibs with secondarymicrocephaly, psychomotor disability
and spastic tetraplegia. Both sibs had a thin corpus callosum
on MRI, which was associated with non-specific white matter
abnormalities in one sib and delayed myelination in the other.
One of the sibs was more severely affected than the other.
Damseh et al (2015) reported nine patients with microcephaly,
hypomyelination, developmental delay and, to a variable ex-
tent, seizures. Heimer et al (2015) reported more patients, who
also presented with developmental disability, spasticity, mi-
crocephaly, seizures and hypomyelination with a thin corpus
callosum on brain MRI. Surprisingly, plasma amino acid con-
centrations were found to be normal in all patients. CSF amino
acids were analysed in only one patient and also found to be
normal. Differentiation of SLC1A4mutations from serine syn-
thesis disorders on clinical grounds appears difficult, although
congenital microcephaly seems to bemore frequent in patients
with serine synthesis defects and cataracts have not been re-
ported in ASCT1 transporter deficiency.
Very low levels of plasma serine and CSF serine have been
observed in patients with disorders other than defects in the
serine synthesis pathway. For instance, low serine values were
observed in patients with disorders of folate metabolism,
Menkes syndrome, complex 1 deficiency, and patients with
overwhelming viral illness (Surtees et al 1997; Keularts et al
2010; personal observations). Reasons for the low serine con-
centrations in folate disorders are obvious given the role of L-
serine in single carbonmetabolism, but one can only speculate
upon the mechanisms giving rise to low serine values in the
other disorders.
Glutamine deficiency
Glutamine deficiency (OMIM 610015) appears to be ultra-
rare among the amino acid synthesis disorders. Since this dis-
order was first reported by Häberle et al 2005, only three
patients in total have been described in the literature
(Häberle et al 2005; Häberle et al 2011).
Glutamine is the most abundant amino acid in human plas-
ma and CSF. It accounts for up to 20% of the total amino acid
content in the human body. Similar to serine, glutamine is an
important metabolite involved in maintaining nitrogen bal-
ance and cellular energy metabolism. However, glutamine
synthetase also plays a key role in regulating the concentra-
tions of ammonia and glutamate in brain tissues by converting
these potential neurotoxic metabolites to glutamine.
The first two patients reported with glutamine deficiency
were severely affected newborns who presented with respira-
tory insufficiency, hypotonia, absence of spontaneous move-
ment and primitive reflexes (Häberle et al 2005). Both patients
developed generalized seizures. One patient died after 2 days
due to cardiac failure. The other patient died after 4 weeks and
had, in addition, severe erythematous skin lesions with blis-
tering and gastro-intestinal symptoms. Cranial MRI of both
patients showed extensive brain abnormalities with cerebral
and cerebellar atrophy and agyria. In one patient, multiple
paraventricular cysts in frontal and temporal lobes were ob-
served. In the other, a gyration pattern resembling that of pre-
term infants was combined with a small cerebellum, white
matter changes and subependymal cysts (Häberle et al 2005).
A third patient with a somewhat milder phenotype present-
ed with neonatal seizures and developed a chronic encepha-
lopathy with intractable seizures resulting in severe psycho-
motor disability (Häberle et al 2011). The boy also suffered
from necrolytic skin abnormalities although this appeared to
be episodic and was not present in the newborn period.
Cranial MRI revealed hypomyelination and a thin corpus
callosum, findings that are also observed in other amino acid
synthesis disorders. Importantly, this patient demonstrates that
glutamine deficiency is not necessarily a lethal disorder and
can give rise to an encephalopathy observed in other amino
acid synthesis disorders as well as many other inborn errors of
metabolism.
Diagnosis
Routine amino acid analysis showed a striking deficiency of
glutamine in plasma, CSF and urine (Table 1). In contrast, the
concentrations of glutamate (the metabolite before the meta-
bolic block) were normal, and only mild and variable
hyperammonemia was observed. The enzymatic defect was
confirmed in immortalized lymphocytes combined with mu-
tation analysis of the glutamine synthetase gene. All mutations
observed in the three patients affected the active site of the
protein (Frieg et al 2016).
It should be noted that, in the patient with the mild pheno-
type, analysis of plasma amino acids at the age of 6 months
demonstrated glutamine values just below the reference range,
indicating that marginally low concentrations of glutamine
should alert us to suspect this diagnosis (Häberle et al 2011).
Finally, low values of plasma glutamine can be associated
with severe illness, in particular in children suffering from
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multiple organ failure in intensive care units (Ekmark et al
2015).
Treatment
No treatment could be attempted in the two severely affected
patients, but treatment was attempted in the third patient
(Häberle et al 2012). This patient was given increasing doses
of L-glutamine, up to 1020 mg/kg/day, that resulted in a cor-
rection of plasma glutamine but only minimal increase of glu-
tamine values in CSF. Despite the fact that biochemical cor-
rection was incomplete, a clear improvement of his EEG ab-
normalities was observed with only minimal improvement in
his clinical status. It seems as in serine deficiency that only
early intervention will result in better clinical outcome.
Recently, also the synthesis of nicotinamide adenine dinu-
cleotide (NAD) was found to be disturbed in this disorder (Hu
et al 2015). The depletion of NAD in cells could be rescued by
nicotineamide supplementation, and this finding may open up
new possibilities for (combined) treatment in affected patients.
Disorders of proline synthesis
The first family with a defect in proline synthesis was reported
more than 15 years ago by Baumgartner et al (2000). Only
recently, mainly due to advances in exome sequencing, many
more patients and other defects in the proline synthesis path-
way have been reported. The clinical spectrum of disorders of
proline synthesis has expanded in a spectacular way. Because
the majority of these patients were diagnosed using molecular
techniques, the disorders are mostly known by their gene sym-
bols and (usually) not classified according to their accompa-
nying enzyme deficiencies. The defects in proline synthesis
are pyroline-5-carboxylate synthase (PSCS or ALDH18A1)
deficiency, pyroline-5-carboxylate reductase 1 (PYCR1) defi-
ciency and pyroline-5-carboxylate reductase 2 (PYCR2)
deficiency.
Most of the patients diagnosed with P5CS deficiency and
PYCR1 deficiency suffered from cutis laxa, and these disor-
ders are therefore classified as autosomal recessive cutis laxa
syndromes (PSCS AR cutis laxa type 2b, type 3a and type3b,
OMIM 138250). However, the discovery of children and
adults with specific heterozygous mutations in ALDH18A1
that lead to autosomal dominant forms of pyroline-5-
carboxylate synthase deficiency (OMIM 616603) shifts our
classical paradigm of autosomal recessive enzyme defects to-
wards that of (de novo) autosomal dominant paediatric and
adult-onset inborn errors of metabolism (Coutelier et al 2015;
Fischer-Zirnsak et al 2015). Since many patients are now be-
ing identified through exome sequencing, these findings have
important implications for our filtering strategies and the in-
terpretation of next generation sequencing (NGS) results, not
only for defects in proline synthesis but for the inborn errors of
metabolism in general.
Pyroline-5-carboxylate synthase deficiency (ALDH18A1)
As in serine deficiency, disorders of proline synthesis can
result in a broad spectrum of symptoms ranging from severe
neonatal forms to adult onset spastic paraplegia.
Infantile cutis laxa phenotype
A deficiency in P5CS will result in a combined deficiency of
L-proline, L-ornithine, L-citrulline and L-arginine, a disorder
first reported by Baumgartner et al (2000). In this first family,
P5CS deficiency was a slowly progressive neurodegenerative
disorder affecting both the central and peripheral nervous sys-
tem, combined with cataracts and extensive connective tissue
involvement. However, the majority of patients with P5CS
deficiency subsequently reported were shown to have a cutis
laxa syndrome (Bicknell et al 2008, Skidmore et al 2011,
Martinelli et al 2012, and others).
The main features in P5CS deficiency are microcephaly,
cutis laxa, progeroid features, mental disability, hypotonia,
seizures, joint laxicity, (intra uterine) growth retardation, and
cataract and corneal abnormalities. In some patients, addition-
al movement disorders such as tremor and dystonia were also
present (Mohamed et al 2011; Zampatti et al 2012; Wolthuis
et al 2014). On cranial MRI, hypomyelination with a thin
corpus callosum can be found, sometimes with cerebellar
abnormalities.
Patients with AR cutis laxa syndromes due to P5CS defi-
ciency show many overlapping features with patients diag-
nosed with PYCR1 deficiency (discussed below). Patients
with P5CS present more often with cataracts and corneal ab-
normalities, symptoms that are rare in PYCR1 deficiency and
abnormalities of plasma amino acids can be observed in P5CS
deficiency. The two disorders can only be discriminated by
their ultrastructural abnormalities in skin biopsies.
Interestingly, Fischer-Zirnsak et al (2015) demonstrated
that de novo dominant mutations in P5CS can also cause a
similar cutis laxa phenotype. They reported eight paediatric
patients with cutis laxa and de novo mutations in ALDH18A1.
All mutations affected the same Arg138 residue of P5CS,
affecting P5CS activity and leading to mislocalisation of the
mitochondrial protein.
As discussed above, de novo dominant mutations are a
challenge for our NGS data filtering strategies and our inter-
pretation of NGS results. Sincemany of the enzymes we study
in metabolic disease are also multimeric protein complexes,
these observations are very relevant for other enzymes in
which dominantmutations affecting dimerization can give rise
to a clinical phenotype.
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Adult spastic paraparesis phenotype
Coutelier et al (2015) reported ALDH18A1mutations in adults
with spastic paraparesis. Autosomal recessive mutations were
associated with a complex spastic paraplegia combined with
cognitive impairment. Surprisingly, heterozygous mutations
in ALDH18A1 were also found in families with autosomal
dominant spastic paraplegia as well as in sporadic spastic
paraplegia patients (suggestive of de novo mutations).
Psychomotor disability and cognitive defects were only
seen in patients with the recessive form and biallelic muta-
tions, whereas lower limb spasticity was the predominant clin-
ical sign in patients with dominant mutations. Less frequent
findings were cataracts, as observed in paediatric cases. The
skin abnormalities including cutis laxa seen in children were
not reported in any of the adult patients.
Panza et al (2016) showed that dominant mutations in
ALDH18A1 are the cause of spastic paraparesis type 9, a dom-
inant spastic paraplegia associated with cataract and cyclic
vomiting. Heterozygous mutations can cause this disorder be-
cause they act as dominant-negative mutations at specific
sites, affecting dimerization of the enzyme complex and hence
enzyme activity. This again supports the paradigm shift in our
field towards (de novo) dominant inborn errors of metabolism
associated with enzyme deficiencies.
Diagnosis
Amino acid analysis in the first family reported with P5CS
deficiency showed a combined deficiency of proline, arginine,
citrulline and ornithine—an unusual combination of amino
acids decreases. Low values of arginine, citrulline and orni-
thine are all observed in urea cycle defects and its related
disorders, but the combination with low proline is only ob-
served in this defect. Plasma ammonia was only mildly in-
creased and decreased after meals in contrast to what happens
in urea cycle disorders.
Surprisingly, in the majority of paediatric patients reported,
no abnormalities were detected in any of the plasma amino
acids, and it is poorly understood why the results of biochem-
ical testing are inconsistent in P5CS deficiency. Timing of
plasma sampling might be one explanation, another might
be whether the mutations are in- or outside the active sites of
the enzyme complex (Panza et al 2016).
The finding of a low creatine peak on brain MRS by
Martinelli et al (2012) is very interesting and certainly could
be of help in other patients too. Low creatine onMRS not only
helps in establishing a diagnosis, but can also potentially be
used to monitor treatment results.
In adults with the recessive form of P5CS deficiency, the
sum of plasma citrulline, ornithine, proline and arginine was
indicative of a deficiency (Coutelier et al 2015). In adults with
the dominant spastic paraplegia, an important reduction in
plasma citrulline was seen in all (4/4) individuals tested, and
this reduction could potentially serve as a diagnostic marker
for P5CS-related spastic paraplegia (Coutelier et al 2015).
As discussed above, many of the (paediatric) patients had
normal plasma amino acids upon testing, and a clinical diag-
nosis is usually confirmed by mutation analysis. As stated
before, it is important to realize that observations of (de novo)
heterozygous mutations with dominant negative effects war-
rant careful interpretation of sequence results, particularly
when NGS strategies are used, and that the presence of a de
novo mutation favours a trio design of testing patient-parent
trios. Confirmation of sequence results that are difficult to
interpret is hampered by the absence of an accessible P5CS
enzyme assay.
Treatment
In the first report, patients were treated with oral L-ornithine.
One patient was treated from the age of five years and the sib
from 12 years. Disappointingly, this treatment with L-
ornithine had no clinical effect. The patient reported by
Martinelli et al (2012), received L-arginine with good effect.
L-Arginine was given because a decreased creatine peak on
MRS was observed and L-arginine therapy restored the low
creatine on spectroscopy. With mental disability being an im-
portant feature in the paediatric patients with P5CS deficiency,
this is an important finding. Unfortunately, no other patients
treated with L-arginine have been reported so far. The findings
of low citrulline in adults with the dominant spastic paraplegia
opens up the possibility of supplementing with L-citrulline,
but results of this therapy have not yet been reported
(Coutelier et al 2015).
Pyroline-5-carboxylate reductase 1 (PYCR1) deficiency
A defect in the gene encoding pyroline-5-carboxylate re-
ductase 1 was first reported by Reversade et al (2009) in
patients with cutis laxa and progeroid features. Mutations
in PYCR1 were found in 35 affected patients (from 22
families) with a phenotype classified as either de Barsy
syndrome, wrinkly-skin syndrome or gerodermia
osteodysplastica (OMIM 179035). In none of these pa-
tients were abnormal plasma concentrations of proline de-
tected. In another large series of patients, Dimopoulou
et al (2013) reported that PYCR1 deficiency can cause a
broad clinical spectrum. Wrinkly skin, joint laxity, typical
facial features, psychomotor disability, osteopenia, intra-
uterine growth retardation and hypotonia were the most
frequently observed and consistent clinical symptoms.
Patients can also suffer from movement disorders similar
to those seen in P5CS deficiency, and paediatric patients
with PYCR1 deficiency share many clinical symptoms
that overlap with those in patients with P5CS deficiency.
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In these large series of patients, mainly missense mutations
were found in PYCR1, with splice site mutations being next,
similar to what is seen in most inborn errors of metabolism.
Dimopoulou et al (2013) reported a genotype-phenotype cor-
relation and demonstrated that patients with mutations in the
first two exons were clinically less severely affected and had
no or very mild intellectual disability.
Adult phenotypes of PYCR1 deficiency likely exist and it
is to be expected that the adult phenotype will resemble adult
forms of P5CS deficiency.
The work of Reversade et al (2009) implicated mitochon-
drial dysfunction in PYCR1 deficiency and increased apopto-
sis as a possible pathogenic mechanism related to the dis-
turbed intracellular proline synthesis. Such a role of PYCR1
in mitochondrial function was recently confirmed by others
(Kuo et al 2016).
Treatment
There are no reports of attempts to treat patients with PYCR1
deficiency with specific (amino acid) therapy.
Diagnosis
Molecular testing is the primary method for diagnosing
PYCR1 deficiency. Biochemical abnormalities were not
found in any of the patients reported.
Pyroline-5-carboxylate reductase 2 (PYCR2) deficiency
PYCR2 deficiency (OMIM 616420) was recently reported as
a cause of secondary microcephaly and hypomyelination
(Nakayama et al 2015). In two consanguineous families, one
from Oman and one from Palestine, four affected children
presented with developmental disability, failure to thrive and
secondary microcephaly. Hypomyelination with a marked re-
duction of white matter volume was found onMRI along with
a thin corpus callosum. Mutations in PYCR2 were detected
because the affected patients shared the same homozygous
region, and a different homozygous missense mutation was
found in each family. The disorder was classified as
hypomyelinating leukodystrophy-10.
Another 18 patients from 11 families with PYCR2 muta-
tions were reported by Zaki et al (2016), expanding the clin-
ical phenotype to that of an even more severe and lethal neu-
rodegenerative disorder. In these patients, microcephaly, se-
vere failure to thrive, profound psychomotor disability, typical
facial features, ataxia and hyperkinetic movement disorders
were observed, often in combination with spastic tetraplegia.
Seizures were present in about half of the patients. The MRI
findings in these patients were somewhat more variable, with
progressive and extensive cortical atrophy as the main feature,
and varying white matter abnormalities and thin corpus
callosum in 60%. None of the reported patients survived be-
yond the age of 10 years, indicative of the severity and poor
prognosis of PYCR2 deficiency.
Like PYCR1, PYCR2 is a mitochondrial protein. Zaki et al
(2016) found evidence that PYCR2 is involved in regulating
apoptosis under conditions of oxidative stress, and the protein
likely plays a role in maintaining mitochondrial membrane
potential. While mitochondrial dysfunction for PYCR1 had
been demonstrated by Reversade et al (2009), a combined role
for PYCR1 and PYCR2 in protection against oxidative stress
was confirmed by Kuo et al (2016). This explains why mito-
chondrial dysfunction and increased lactate on brain MRS can
be observed in PYCR2 deficiency (personal observations).
Treatment
Similar to PYCR1 deficiency, there are no reports of treatment
with amino acids in PYCR2 deficiency.
Diagnosis
In patients with PYCR2 deficiency no biochemical abnormal-
ities were observed. In particular, plasma proline was always
normal. The only abnormal findings were marginal elevations
of glutamate excretion in two patients tested for amino acid
excretion in urine. Molecular testing is necessary to confirm a
clinical diagnosis of PYCR2 deficiency.
Asparagine deficiency
Similar to many of the patients with defects in proline synthe-
sis, patients with a defect in asparagine were diagnosed
through exome sequencing strategies. The first patients with
asparagine deficiency (OMIM 615574) caused by defects in
asparagine synthetase (ASNS) were reported by Ruzzo et al
(2013). Of nine patients from four families, the majority had
an epileptic encephalopathy with intractable seizures, progres-
sive (congenital) microcephaly, severe developmental disabil-
ity, axial hypotonia and spastic tetraplegia. As an additional
clinical feature, acoustic startles and symptoms resembling
hyperekplexia were observed in one of the families.
On MRI, decreased cerebral volume was seen in all pa-
tients, combined with a decreased size of the pons and a sim-
plified gyration pattern in 6/9 patients. In some patients, pro-
gressive MRI abnormalities were noted on follow-up scans.
As is not uncommon in epileptic encephalopathies associated
with metabolic diseases, multiple seizure types and EEG ab-
normalities were present. All patients had missense mutations
in the ASNS gene.
In 2015, Ben-Salem et al reported another child with con-
genital microcephaly who presented at day one with myoclon-
ic seizures, did not acquire any developmental milestones and
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developed a severe spastic tetraplegia. He had pale optic discs
and absence of visual responses. The MRI findings in this
patient were more severely abnormal and also showed a de-
creased cerebral volume with atrophy of the corpus callosum
and a marked ventriculomegaly. A third family with two af-
fected sibs was described by Alfadhel et al (2015).
Seidahmed et al (2016) described two patients from unrelat-
ed families with excessive startles resembling hyperekplexia.
The (acoustic) startles were striking clinical findings, including
non-habituation of the head retraction reflex on glabellar and
nose-tapping. In these two patients, truncal hypotonia was ev-
ident, which is in contrast with children with hyperekplexia
who have generalized stiffness. Acoustic startles and non-
habituation of the head-retraction reflex can provide important
diagnostic clues to asparagine deficiency.
In patients for whom follow-up was reported, not only the
clinical course and microcephaly, but also the abnormalities
on MRI that were progressive. All these symptoms indicate
that asparagine synthetase deficiency is a (slowly) progressive
neurodegenerative disorder similar to PYCR2 deficiency
(Palmer et al 2015).
A rapidly progressive course of disease has also been re-
ported by Sun et al (2016) in two sibs who had, in addition, an
eventration of the diaphragm resulting in severe respiratory
complications. Although this may be a rare coincidental asso-
ciation, it was the first abnormality reported outside the central
nervous system in this disorder and warrants careful investi-
gation of multiple organ involvement.
Asparagine synthetase catalyses the transfer of ammonia
from glutamine to aspartic acid to form asparagine, which is a
ubiquitously expressed enzyme. Palmer et al (2015) found no
correlation between the clinical phenotype and the effect of
mutations on protein expression in model systems. It is
puzzling how a ubiquitously expressed enzyme defect can
affect the central nervous system in such a specific way, and
we see a similar puzzling effect in the glutamine and proline
synthesis disorders. Palmer et al (2015) showed in cultured skin
fibroblasts of patients with asparagine deficiency that growth is
restricted under conditions of limited availability of asparagine
in the culture medium, and suggested that a similar mechanism
may explain the central nervous system abnormalities.
Diagnosis
Ruzzo et al (2013) commented on the potential pitfalls of a
biochemical diagnosis in asparagine deficiency. Apart from
our traditional focus on increased asparagine levels in catabol-
ic amino acid disorders, asparagine levels are normally low in
plasma and the lower range for asparagine in CSF is set at
0 mmol/l in many laboratories. In consequence, decreases in
asparagine levels may not be noticed or picked up during the
diagnostic process. However, low values of asparagine were
indeed found in just over half of the families reported to date,
with inconsistent elevations of glutamine. This means that
while asparagine synthetase deficiency can be suspected on
the basis of low values in plasma or CSF, it cannot be ruled out
by normal values, making biochemical testing for this inborn
error inferior to molecular testing.
Treatment
Treatment was attempted in a single patient reported by Alrifai
andAlfadhel (2016). In a 5.5-year-old boy, L-asparagine therapy
resulted in minimal improvement of mental status/conscious-
ness. However, it also led, surprisingly, to a worsening of his
seizures, and the amino acid therapy was discontinued. The
authors suggest that, similar to treatment in serine deficiency,
only very early or prenatal therapy might result in prevention
or amelioration of the neurological abnormalities. However, the
authors warn not to draw firm conclusions from the results of
treatment observed in this single case. Symptomatic treatment of
the seizures appeared problematic in the reported cases, but
Alrifai and Alfadhel (2016) found a favourable effect on the
seizure frequency in their patient using high dose valproate.
Conclusions
Defects in the synthesis pathways of the non-essential amino
acids L-serine, L-glutamine, L-proline and L-asparagine pre-
dominantly affect the central nervous system, in particular in
the infantile-onset forms. Interestingly, the synthesis defects
have some clinical characteristics in common including micro-
cephaly, psychomotor disability, seizures and white matter ab-
normalities on MRI. Defects in the synthesis of serine, gluta-
mine and proline are also associated with specific symptoms of
the skin, including collodion-like skin in serine deficiency,
necrolytic erythema in glutamine deficiency and cutis laxa in
proline synthesis disorders.We have learned in recent years that
serine and proline deficiency disorders give rise to a broad
spectrum of clinical phenotypes with a lethal (foetal) phenotype
on one end and adult-onset neurological disease on the other.
In contrast to the spectacular gain of insight into the clinical
spectrum we have witnessed in amino acids synthesis disor-
ders, reports on how to treat these disorders are still rare, but
promising in the serine synthesis disorders. Treatment should
therefore gain more attention given the potential benefits of
supplementing missing substrates. Whole exome sequencing
has proven to be invaluable for elucidation of some of these
disorders. Biochemical investigation, traditionally our first ap-
proach in patients with a suspected inborn error of metabo-
lism, is insufficient, at least for diagnosing patients with pro-
line and asparagine synthesis defects.
The observation that dominant mutations can also cause
amino acid synthesis disorders will shift our classical para-
digm of recessive inborn errors of metabolism. This shift
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requires careful interpretation of molecular diagnostics and
the further development of functional assays for these amino
acid disorders primarily approached by NGS techniques.
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